CO6670577A2 - Derivados de heterocíclicos fusionados como moduladores s1p - Google Patents

Derivados de heterocíclicos fusionados como moduladores s1p

Info

Publication number
CO6670577A2
CO6670577A2 CO13014079A CO13014079A CO6670577A2 CO 6670577 A2 CO6670577 A2 CO 6670577A2 CO 13014079 A CO13014079 A CO 13014079A CO 13014079 A CO13014079 A CO 13014079A CO 6670577 A2 CO6670577 A2 CO 6670577A2
Authority
CO
Colombia
Prior art keywords
optionally substituted
alkyl
halogen
atoms
fluorine
Prior art date
Application number
CO13014079A
Other languages
English (en)
Inventor
Pieter Smid
Bakker Wouter Iwema
Hien K A C Coolen
Leonardus A J M Sliedregt
Dongen Maria J P Van
Hartog Jacobus A J Dan
Original Assignee
Abbvie Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44358260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6670577(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Bv filed Critical Abbvie Bv
Publication of CO6670577A2 publication Critical patent/CO6670577A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con un derivado heterocíclico fusionado de la fórmula (I)en dondeR1 se selecciona de ciano, alquenilo (C2-4), alquinilo (C2-4), alquilo (C1-4), cada uno opcionalmente sustituido con CN o uno o más átomos de flúor, cicloalquilo (C3-6), cicloalquenilo (C4-6) o un grupo bicíclico (C8-10), cada uno opcionalmente sustituido con halógeno o alquilo (C1-4) opcionalmente sustituido con uno o más átomos de flúor, fenilo, bifenilo, naftilo, cada uno opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, ciano, alquilo (C1-4) opcionalmente sustituido con uno o más átomos de flúor, alcoxi (C1-4) opcionalmente sustituido con uno o más átomos de flúor, amino, dimetilamino, y cicloalquilo (C3-6) opcionalmente sustituido con fenilo que se puede sustituir con alquilo (C1-4) o halógeno, y fenilo sustituido con fenoxi, bencilo, benciloxi, feniletilo o heterociclo monocíclico, cada uno opcionalmente sustituido con alquilo (C1-4),Z es un grupo de enlace -W-(alquileno C)-T- en dondeW se adhiere a Rl y se selecciona de un enlace, -O-, -CO-, -S-, - SO-, -SO-, -NH-, -CH=CH-, -C(CF)=CH-, -CC-, -CH-O-, -O-CO-, -CO-O-, -CONH-, -NH-C0- y trans-ciclopropileno; n es un entero de 0 a 10; yT se adhiere al grupo funcional fenilenol piridilo y se selecciona de un enlace, -0-, -S-, -SO-, -SO-, -NH-, -CO-, -C=C-, -C?C-, y trans-ciclopropileno;R2 es H o uno o más sustituyentes seleccionados independientemente de ciano, halógeno, alquilo (C1-4) opcionalmente sustituido con uno o más átomos de halógeno, o alcoxi (C1-4) opcionalmente sustituido con uno o más átomos de halógeno; la estructura del anillo A puede contener un átomo de nitrógeno;X se selecciona de C o N; si X es C, R3 se selecciona de H y alquilo (C1-4), de otra forma R3 no está presente;
CO13014079A 2010-07-09 2013-01-25 Derivados de heterocíclicos fusionados como moduladores s1p CO6670577A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36278410P 2010-07-09 2010-07-09
EP10169107 2010-07-09
US201161446541P 2011-02-25 2011-02-25
EP11156007 2011-02-25

Publications (1)

Publication Number Publication Date
CO6670577A2 true CO6670577A2 (es) 2013-05-15

Family

ID=44358260

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13014079A CO6670577A2 (es) 2010-07-09 2013-01-25 Derivados de heterocíclicos fusionados como moduladores s1p

Country Status (27)

Country Link
US (3) US8796262B2 (es)
EP (1) EP2590980B1 (es)
JP (1) JP5973429B2 (es)
KR (1) KR101889694B1 (es)
CN (1) CN103068827B (es)
AR (1) AR082136A1 (es)
AU (1) AU2011275755B2 (es)
BR (1) BR112013000627B1 (es)
CA (1) CA2804137C (es)
CL (1) CL2013000069A1 (es)
CO (1) CO6670577A2 (es)
CR (1) CR20130056A (es)
DO (1) DOP2013000009A (es)
EC (1) ECSP13012416A (es)
ES (1) ES2653682T3 (es)
HK (1) HK1179956A1 (es)
IL (1) IL224054A (es)
MX (1) MX2013000360A (es)
MY (1) MY161229A (es)
NZ (1) NZ605491A (es)
PE (1) PE20130592A1 (es)
RU (1) RU2576660C2 (es)
SG (1) SG186952A1 (es)
TW (1) TWI522361B (es)
UY (1) UY33496A (es)
WO (1) WO2012004373A1 (es)
ZA (1) ZA201300157B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48301E1 (en) 2010-07-09 2020-11-10 Abbvie B.V. Fused heterocyclic derivatives as S1P modulators
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
JP2016011257A (ja) * 2012-10-23 2016-01-21 大日本住友製薬株式会社 テトラヒドロオキサゾロピリジン誘導体
EP3341369A1 (en) * 2015-08-28 2018-07-04 AbbVie Inc. Fused heterocyclic compounds as s1p modulators
EP3535244A1 (en) 2016-11-02 2019-09-11 Abbvie Deutschland GmbH & Co. KG Spiro-compounds as s1p modulators
BR112022008137A2 (pt) * 2019-10-31 2022-07-19 Escape Bio Inc Processos para preparar um modulador de receptor s1p
CA3159378A1 (en) * 2019-10-31 2021-05-06 ESCAPE Bio, Inc. Solid forms of an s1p-receptor modulator
JP7307282B2 (ja) * 2020-03-04 2023-07-11 ヒーリオイースト ファーマシューティカル カンパニー リミテッド ベンゾ２－アザスピロ［４．４］ノナン系化合物及びその使用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069387A1 (ru) * 1982-07-01 1985-11-30 Институт физико-органической химии и углехимии АН УССР Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием
GB2228432A (en) 1989-01-13 1990-08-29 Grayston Central Services Multi-role machine for heating and coating pipe welds.
JPH03206042A (ja) * 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
JP2681589B2 (ja) 1992-12-28 1997-11-26 日揮株式会社 配管溶接継手の熱処理方法
JPH072848A (ja) 1993-04-23 1995-01-06 Sankyo Co Ltd モルホリンおよびチオモルホリン誘導体
GB9522845D0 (en) 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
JP3822680B2 (ja) 1996-08-30 2006-09-20 新日本製鐵株式会社 誘導加熱された接合部の冷却方法および冷却装置
JP3974781B2 (ja) 2000-04-21 2007-09-12 塩野義製薬株式会社 抗癌作用を有するオキサジアゾール誘導体
FR2822727A1 (fr) 2001-04-03 2002-10-04 Gesal Ind Procede d'application d'un revetement resistant aux hautes temperatures, dispositif pour la mise en oeuvre de ce procede et objet pourvu dudit revetement
JP3649223B2 (ja) 2003-01-08 2005-05-18 株式会社日立製作所 配管系の熱処理方法および熱処理装置
US7265128B2 (en) * 2003-01-17 2007-09-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2526209A1 (en) 2003-06-12 2004-12-23 Btg International Limited Cyclic hydroxylamine as psychoactive compounds
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0409744D0 (en) 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
AU2005238296A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
ES2398694T3 (es) * 2004-06-30 2013-03-21 Athersys, Inc. Derivados de azepina sustituidos como moduladores de receptores de serotonina
JP2008517915A (ja) 2004-10-22 2008-05-29 メルク エンド カムパニー インコーポレーテッド Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環
JP4491334B2 (ja) 2004-12-01 2010-06-30 日立Ｇｅニュークリア・エナジー株式会社 配管の熱処理方法および装置
JP4599250B2 (ja) 2005-08-10 2010-12-15 株式会社東芝 高周波誘導加熱時外面温度制御方法および当該制御装置
JP2007063642A (ja) 2005-09-01 2007-03-15 Hitachi Ltd 残留応力改善方法と高周波誘導加熱用コイル
GB0520164D0 (en) * 2005-10-04 2005-11-09 Novartis Ag Organic compounds
JP2009525280A (ja) * 2006-01-30 2009-07-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｐａｒモジュレーターとしての化合物および組成物
ES2462240T3 (es) 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
US20100009969A1 (en) * 2006-07-27 2010-01-14 Ucb Pharma, S.A. Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands
EP2081888A1 (en) 2006-09-08 2009-07-29 Novartis AG N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions
MX2009006751A (es) 2006-12-21 2009-06-30 Abbott Lab Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato.
CN101668741A (zh) * 2007-01-11 2010-03-10 阿勒根公司 具有鞘氨醇-1-磷酸(s1p)受体拮抗剂生物学活性的6-取代吲哚-3-羧酸酰胺化合物
EP2364976B1 (en) 2007-03-21 2014-10-08 EPIX Pharmaceuticals, Inc. S1P receptor modulating compounds and use thereof
EP2148863A1 (en) 2007-04-23 2010-02-03 Novartis Ag Phthalazine and isoquinoline derivatives with slp receptor modulating activities
WO2009084501A1 (ja) * 2007-12-27 2009-07-09 Asahi Kasei Pharma Corporation スルタム誘導体
WO2009092764A1 (en) * 2008-01-24 2009-07-30 Ucb Pharma, S.A. Compounds comprising a cyclobutoxy group
MX2010008382A (es) 2008-01-30 2010-11-25 Cephalon Inc Derivados de piperidina espirociclicos substituidos, como ligandos de receptores de histamina-3 (h3).
JP5524083B2 (ja) 2008-01-30 2014-06-18 セファロン、インク． ヒスタミン−３（ｈ３）受容体リガンドとしての置換スピロ環状ピペリジン誘導体
US20090321144A1 (en) 2008-06-30 2009-12-31 Wyble Kevin J Protecting an element from excessive surface wear by localized hardening
UY32858A (es) 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
SG10201500832PA (en) 2010-02-04 2015-04-29 Esteve Labor Dr 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
CN101812058B (zh) 2010-04-13 2012-03-21 湖南大学 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用
TW201206893A (en) * 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators

Also Published As

Publication number Publication date
US20140066433A1 (en) 2014-03-06
AU2011275755A8 (en) 2013-02-14
NZ605491A (en) 2014-08-29
KR20140005849A (ko) 2014-01-15
TWI522361B (zh) 2016-02-21
RU2576660C2 (ru) 2016-03-10
JP5973429B2 (ja) 2016-08-23
ES2653682T3 (es) 2018-02-08
KR101889694B1 (ko) 2018-08-21
SG186952A1 (en) 2013-02-28
AU2011275755B2 (en) 2015-04-09
CR20130056A (es) 2013-06-12
IL224054A (en) 2016-07-31
CA2804137C (en) 2019-06-11
AU2011275755A1 (en) 2013-01-31
JP2013531002A (ja) 2013-08-01
ZA201300157B (en) 2017-05-31
US9096612B2 (en) 2015-08-04
RU2013105444A (ru) 2014-08-20
CN103068827B (zh) 2016-05-04
CN103068827A (zh) 2013-04-24
BR112013000627A2 (pt) 2016-05-24
BR112013000627B1 (pt) 2020-12-08
US20150284403A1 (en) 2015-10-08
DOP2013000009A (es) 2013-10-15
ECSP13012416A (es) 2013-03-28
CL2013000069A1 (es) 2013-06-07
CA2804137A1 (en) 2012-01-12
US20130203737A1 (en) 2013-08-08
US8796262B2 (en) 2014-08-05
TW201206945A (en) 2012-02-16
EP2590980B1 (en) 2017-09-20
WO2012004373A1 (en) 2012-01-12
UY33496A (es) 2012-01-31
HK1179956A1 (zh) 2013-10-11
MY161229A (en) 2017-04-14
AR082136A1 (es) 2012-11-14
EP2590980A1 (en) 2013-05-15
US9670220B2 (en) 2017-06-06
MX2013000360A (es) 2013-06-28
PE20130592A1 (es) 2013-05-22

Similar Documents

Publication Publication Date Title
CO6670577A2 (es) Derivados de heterocíclicos fusionados como moduladores s1p
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
PE20160546A1 (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4
EA201390022A8 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ)
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
CY1112102T1 (el) Υποκατεστημενες πυριμιδοδιαζεπινες χρησιμες ως αναστολεις plk1
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR078609A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros.
AR077849A2 (es) Compuestos y composiciones como inhibidores de proteina quinasa
PE20130188A1 (es) Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
CR20130349A (es) COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
AR076067A1 (es) Composiciones y metodos para modular la senda de senalizacion de wnt
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
ECSP11010912A (es) Compuestos de pirrol
AR093184A1 (es) Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden
BR112013008675A2 (pt) métodos e composições para o tratamento de diabetes e dislipidemia
EA200870191A1 (ru) Новые производные циклической мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназ
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
DOP2010000226A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos
CO5601021A2 (es) Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
EA201391717A1 (ru) Ингибиторы вируса гепатита с

Legal Events

Date Code Title Description
FG Application granted